BDPI USP - Resultado da busca

First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial (2018)

Rimawi, Mothaffar; Ferrero, Jean-Marc; Haba-rodriguez, Juan de la; Poole, Christopher; Placido, Sabino De; Osborne, C. Kent; Hegg, Roberto; Easton, Valerie; Wohlfarth, Christine; Arpino, Grazia

In: Journal of clinical oncology. Unidade: FM

Subjects: Neoplasias Mamárias, Quimioterapia Adjuvante, Inibidores De Enzimas, Receptores De Esteroides, Metástase Neoplásica

Acesso à fonte DOI

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

ABNT
RIMAWI, Mothaffar; FERRERO, Jean-Marc; HABA-RODRIGUEZ, Juan de la; et al. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. Journal of clinical oncology, Alexandria, v. 36, n. 28, p. 2826-2835, 2018. Disponível em: < http://observatorio.fm.usp.br/handle/OPI/29994 > DOI: 10.1200/JCO.2017.76.7863.
APA
Rimawi, M., Ferrero, J. -M., Haba-rodriguez, J. de la, Poole, C., Placido, S. D., Osborne, C. K., et al. (2018). First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. Journal of clinical oncology, 36( 28), 2826-2835. doi:10.1200/JCO.2017.76.7863
NLM
Rimawi M, Ferrero J-M, Haba-rodriguez J de la, Poole C, Placido SD, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial [Internet]. Journal of clinical oncology. 2018 ; 36( 28): 2826-2835.Available from: http://observatorio.fm.usp.br/handle/OPI/29994
Vancouver
Rimawi M, Ferrero J-M, Haba-rodriguez J de la, Poole C, Placido SD, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial [Internet]. Journal of clinical oncology. 2018 ; 36( 28): 2826-2835.Available from: http://observatorio.fm.usp.br/handle/OPI/29994

ReP

Filters

USP Schools

ReP

Filters

Document types

USP Schools

Departament

Authors

USP affiliated authors

Date published

Subjects

Source title

Publisher

Conference title

Grupo de pesquisa

Funding Agencies

Indexado em

Normalized affiliation

Non normalized affiliation

Countries of institutions of collaboration

Keywords